Abstract: Combined use of a heparin cofactor II agonist and a platelet GPIIb/IIIa receptor antagonist to inhibit both platelet aggregation and thrombin generation resulting from disease, injury or responses to wound repairs. The combined use of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist can achieve these therapeutic benefits while at the same time minimizing or reducing the risk of hemorrhagic side effects (e.g., prolonged bleeding), and without causing undesired antigenic responses. Moreover, certain subtherapeutic amounts of the heparin cofactor II agonist with certain subtherapeutic amounts of a platelet GPIIb/IIIa receptor antagonist can, in combination, be therapeutically effective in inhibiting both platelet aggregation and thrombin generation.

Abstract: A selectively targeted agent comprising a dermatan sulfate having more than about 25% repeating L-iduronic acid→4,6-di-O-sulfated N-acetyl-D-galactosamine disaccharide units that is covalently attached or bonded to a radioactive metal-ion binding moiety. The targeted agent is useful in preparing radiagnostic and/or radiopharmaceutical agents for diagnostic and/or therapeutic treatment when combined with an appropriate radioactive metal ion such as 99mTc, 186Re or 188Re.

Abstract: Combined use of a heparin cofactor II agonist and a platelet GPIIb/IIIa receptor antagonist to inhibit both platelet aggregation and thrombin generation resulting from disease, injury or responses to wound repairs. The combined use of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist can achieve these therapeutic benefits while at the same time minimizing or reducing the risk of hemorrhagic side effects (e.g., prolonged bleeding), and without causing undesired antigenic responses. Moreover, certain subtherapeutic amounts of the heparin cofactor II agonist with certain subtherapeutic amounts of a platelet GPIIb/IIIa receptor antagonist can, in combination, be therapeutically effective in inhibiting both platelet aggregation and thrombin generation.

Abstract: A method of inhibiting thrombin generation and of inhibiting complement activation by using a dermatan sulfate having at least 2 sulfate groups per disaccharide obtained by chemical sulfation of native dermatan sulfate. The resulting dermatan sulfate having an average molecular weight from about 5000 to 35000 Daltons is characterized by (i) a high content of L-iduronic->4,6-di-O-sulfated N-acetyl-D-galactosamine residues, and (ii) a specific heparin cofactor II-mediated anti-thrombin activity, depending on average molecular weight, between about 25 to 125 U/mg.

Abstract: A protein hydrolyzate is produced from mucosa tissue of pigs, cattle or sheep by providing an aqueous mixture of the tissue, hydrolyzing the tissue with a proteolytic enzyme at a salt concentration of less than 0.1 molar to produce a digest solution containing a protein hydrolyzate and polyanions including heparin, adsorbing the polyanions on an anion exchange resin, recovering the anion exchange resin containing adsorbed polyanions to provide a digest solution containing less than 2.9 u/ml residual heparin and recovering the protein hydrolyzate from the digest solution by screening or dehydration. The protein hydrolyzate contains less than 15% ash, between 9.5 and 11.5% total Kjeldahl nitrogen and between 5.0 and 7.0% alpha amino nitrogen. The protein hydrolyzate may be used in nutritional formulations such as to promote weight gain in newly weaned livestock and in medical formulations such as peritoneal dialysis fluids and formulations for use in enteral and parenteral mutrition.

Abstract: Regression of established malignant tumors in rats, mice and hamsters is achieved with a combination of the heparin fragment hexuronyl hexosaminoglycan sulfate (HHS) together with a steroid such as hydrocortisone. HHS is clinically useful for its antineoplastic, inhibiting effects in tumor systems in rats, mice and hamsters.